CLRB (Cellectar Biosciences INC NEW)
Insider Trading Activity
Every open-market purchase and sale reported by CLRB officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-10 | Stefan Loren | — | A | — | — |
| 2026-07-08 | Asher Chanan-Khan | Director | A | — | — |
| 2026-07-08 | FREDERICK W DRISCOLL | Director | A | — | — |
| 2026-07-08 | JOHN NEIS | Director | A | — | — |
| 2026-07-08 | JAMES V CARUSO | President & CEO | A | — | — |
| 2026-07-08 | Stefan Loren | — | A | — | — |
| 2026-07-08 | Andrew Gu | Director | A | — | — |
| 2026-07-08 | Douglas J Swirsky | Director | A | — | — |
| 2026-07-08 | Chad J Kolean | CFO | A | — | — |
| 2026-07-08 | Jarrod Longcor | Chief Operating Officer | A | — | — |
| 2026-05-11 | Jarrod Longcor | Chief Operating Officer | Buy | — | — |
| 2026-05-11 | JAMES V CARUSO | Chief Executive Officer | Buy | — | — |
| 2025-12-16 | JOHN NEIS | Director | Sell | — | — |
| 2025-07-03 | Jarrod Longcor | Chief Operating Officer | Buy | — | — |
| 2025-07-03 | JAMES V CARUSO | Chief Executive Officer | Buy | — | — |
| 2025-07-03 | Chad J Kolean | Chief Financial Officer | Buy | — | — |
| 2025-03-12 | Jarrod Longcor | Chief Operating Officer | Buy | — | — |
| 2025-02-18 | Douglas J Swirsky | Director | A | — | — |
| 2025-02-18 | JAMES V CARUSO | President and CEO | A | — | — |
| 2025-02-18 | Chad J Kolean | Chief Financial Officer | A | — | — |
| 2025-02-18 | Jarrod Longcor | Chief Operating Officer | A | — | — |
| 2025-02-18 | JOHN NEIS | Director | A | — | — |
| 2025-02-18 | FREDERICK W DRISCOLL | Director | A | — | — |
| 2025-02-18 | Asher Chanan-Khan | Director | A | — | — |
| 2025-02-18 | Stefan Loren | Director | A | — | — |
| 2024-06-18 | Darrell Shane Lea | Chief Commercial Officer | A | — | — |
| 2024-06-18 | Andrei Shustov | Senior Vice President, Medical | A | — | — |
| 2024-06-18 | FREDERICK W DRISCOLL | Director | A | — | — |
| 2024-06-18 | JOHN NEIS | Director | A | — | — |
| 2024-06-18 | Asher Chanan-Khan | Director | A | — | — |
| 2024-06-18 | Stefan Loren | Director | A | — | — |
| 2024-06-18 | Douglas J Swirsky | Director | A | — | — |
| 2024-06-18 | Chad J Kolean | Chief Financial Officer | A | — | — |
| 2024-06-18 | Jarrod Longcor | Chief Operating Officer | A | — | — |
| 2024-06-18 | JAMES V CARUSO | President and CEO | A | — | — |
| 2023-12-12 | Jarrod Longcor | Chief Operating Officer | A | — | — |
| 2023-12-12 | Chad J Kolean | Chief Financial Officer | A | — | — |
| 2023-12-12 | Darrell Shane Lea | Chief Commercial Officer | A | — | — |
| 2023-12-12 | JAMES V CARUSO | President and CEO | A | — | — |
| 2023-12-12 | Andrei Shustov | Senior Vice President, Medical | A | — | — |
| 2023-06-28 | FREDERICK W DRISCOLL | Director | A | — | — |
| 2023-06-28 | Douglas J Swirsky | Director | A | — | — |
| 2023-06-28 | Asher Chanan-Khan | Director | A | — | — |
| 2023-06-28 | Stefan Loren | Director | A | — | — |
| 2023-06-28 | JOHN NEIS | Director | A | — | — |
| 2023-03-16 | Andrei Shustov | Senior Vice President, Medical | A | — | — |
| 2023-01-18 | JAMES V CARUSO | President and CEO | A | — | — |
| 2023-01-18 | Jarrod Longcor | Chief Operating Officer | A | — | — |
| 2023-01-18 | Chad J Kolean | Chief Financial Officer | A | — | — |
| 2022-12-15 | Darrell Shane Lea | Chief Commercial Officer | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chief Operating Officer | 20,451 | — |
| — | President & CEO | 20,318 | — |
| — | CFO | 6,418 | — |
| — | Senior Vice President, Medical | 1,835 | — |
| — | Chief Commercial Officer | 1,320 | — |
| — | Director | 83 | — |
| — | Director | 65 | — |
| — | Director | 10 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CLRB quote page; the site-wide leaderboard is on the insider transactions hub.